Premium
Prescriptions of systemic antibiotics for children in Germany aged between 0 and 6 years
Author(s) -
Schindler Christoph,
Krappweis Jutta,
Morgenstern Ingolf,
Kirch Wilhelm
Publication year - 2003
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.786
Subject(s) - medicine , antibiotics , medical prescription , penicillin , respiratory tract infections , bronchitis , pediatrics , cephalosporin , tonsillitis , systemic antibiotics , cefixime , pharmacology , respiratory system , microbiology and biotechnology , biology
Limited information is available about systemic antibiotic use among children in Germany. We therefore assessed prescription patterns by office‐based physicians to analyse antibiotic consumption in early childhood. A total of 331 children < 6 years were eligible for inclusion. The number of antibiotic prescriptions, consumed daily doses, number of treatment courses, types of antibiotics and diagnoses for prescribing were determined. The prevalence of systemic antibiotic treatment was 42.9%. Antibiotic consumption was highest between 2 and 3 years of age (55.8%). The percentage of children receiving one, two or three courses of antibiotic treatment was 49.3, 28.2 and 16.2%, respectively. Acute otitis media (32.2%), upper respiratory tract infections (18.9%), tonsillitis (15.9%) and acute bronchitis (15.4%) were principal indications for treatment. Macrolides were most frequently prescribed (48.1%), followed by penicillin V (21.3%), broad‐spectrum penicillins (14.3%), sulfonamides (10.5%) and cephalosporins (5.8%). Antibiotics not recommended for particular indication were selected in 5–43% of cases. The considerable prescription of systemic antibiotics to children in many European countries is also the case in Germany. A noteworthy trend emerged for suboptimal prescribing with second‐line antibiotics. As such treatment may be associated with the development of bacterial resistance, improved guidelines for antibiotic treatment should be drawn up and enforced. Copyright © 2002 John Wiley & Sons, Ltd.